secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001193125-22-275336
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Silverback Therapeutics announces final exchange ratio of 1.1819 for merger with ARS Pharma
--------------------------------------------------------------------------------

- Final exchange ratio set at 1.1819 per the Merger Agreement as amended on October 25, 2022.
- Merger with ARS Pharmaceuticals remains subject to stockholder approval and other closing conditions.
- Shareholders are urged to read the definitive proxy statement filed on October 6, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522275336/0001193125-22-275336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522275336/d408267d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-275336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer